Skip to Content

Perflutren Side Effects

It is possible that some side effects of perflutren may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to perflutren: intravenous suspension

As well as its needed effects, perflutren may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking perflutren, check with your doctor or nurse immediately:

  • Black, tarry stools
  • blurred vision
  • chest pain
  • chills
  • difficulty with breathing
  • dizziness, severe or continuing
  • fast, pounding, or irregular heartbeat or pulse
  • hives
  • itching
  • lightheadedness when getting up from a lying or sitting position
  • shortness of breath
  • skin rash
  • slow or irregular heartbeat
  • swollen glands
  • unusual bleeding or bruising
Incidence not known
  • Cough
  • difficulty swallowing
  • dizziness
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • tightness in the chest
  • unusual tiredness or weakness
  • wheezing

Some perflutren side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

Less common
  • Back pain
  • feeling of warmth on the skin
  • headache
  • nausea
  • redness of the face, neck, arms, and occasionally, upper chest
  • Acid or sour stomach
  • bruising
  • diarrhea
  • difficulty with moving
  • dizziness
  • dryness of the mouth
  • feeling of constant movement of self or surroundings
  • fever
  • heartburn
  • indigestion
  • leg cramps
  • muscle stiffness or tension
  • pain at the injection site
  • pain or swelling in the joints
  • prickly or tingling sensation
  • sneezing or runny nose
  • stomach upset or pain

For Healthcare Professionals

Applies to perflutren: intravenous suspension


The most frequently reported adverse reactions were headache, nausea and/or vomiting, warm sensation or flushing, dizziness, and back pain.[Ref]


Common (1% to 10%): Chest pain
Uncommon (0.1% to 1%): Abnormal ECGs, bradycardia, tachycardia, palpitation, hypertension, hypotension
Postmarketing reports: Fatal cardiac arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation/tachycardia), hypertension, hypotension[Ref]

Serious but uncommon cardiopulmonary reactions, including fatalities, have been reported during or following administration of this medication. Most serious reactions occurred within 30 minutes of administration.

QTc prolongation of greater than 30 milliseconds occurred in 29% (64/221) of patients evaluated. Of these patients 72% (46/64) were further evaluated and 39% (18/46) were found to have cardiac rhythm changes. (Definity(R))[Ref]


Uncommon (0.1% to 1%): Coughing, hypoxia, pharyngitis, rhinitis, dyspnea
Postmarketing reports: Fatal respiratory arrest, dyspnea, hypoxia, respiratory distress, stridor, wheezing[Ref]


Postmarketing reports: Anaphylactic/anaphylactoid reactions[Ref]

Postmarketing reports of anaphylactic/anaphylactoid reactions have included: anaphylactic shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema.[Ref]


Common (1% to 10%): Flushing
Uncommon (0.1% to 1%): Pruritus, rash, erythematous rash, urticaria, increased sweating, dry skin[Ref]


Common (1% to 10%): Nausea
Uncommon (0.1% to 1%): Dyspepsia, dry mouth, tongue disorder, abdominal pain, diarrhea, vomiting[Ref]


Uncommon (0.1% to 1%): Albuminuria[Ref]


Uncommon (0.1% to 1%): Granulocytosis, leukocytosis, leukopenia, eosinophilia, hematoma[Ref]


Uncommon (0.1% to 1%): Injection site reaction[Ref]


Common (1% to 10%): Back pain
Uncommon (0.1% to 1%): Arthralgia[Ref]

Nervous system

Common (1% to 10%): Headache
Uncommon (0.1% to 1%): Leg cramps, hypertonia, vertigo, paresthesia, dizziness, taste perversion
Postmarketing Reports: Coma, loss of consciousness, convulsion, seizure, transient ischemic attack, agitation, tremor, vision blurred, dizziness, headache, fatigue[Ref]


Uncommon (0.1% to 1%): Conjunctivitis, abnormal vision[Ref]


Uncommon (0.1% to 1%): Decreased hearing[Ref]


Common (1% to 10%): Renal pain[Ref]


1. Cerner Multum, Inc. "Australian Product Information." O 0

2. "Product Information. Optison (perflutren)." Mallinckrodt Medical Inc, St. Louis, MO.

3. "Product Information. Definity (perflutren)." Lantheus Medical Imaging Inc, North Billerica, MA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.